2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vomiting
13
Nausea
6
Neoplasms
5
Multiple Myeloma
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
1
Ovarian Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Melanoma
1
Gynecologic Cancer
1
Genital Neoplasms, Female
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
5
Paclitaxel
4
pembrolizumab
3
Educational Status
3
niraparib
2
anlotinib
2
Therapeutic Touch
2
Surveys and Questionnaires
2
Standard of Care
2
Radiotherapy
2
Pemetrexed
2
Palliative Care
2
Nivolumab
2
Methods
2
Interviews as Topic
2
Gemcitabine
2
Early Intervention, Educational
2
Bevacizumab
2
temsirolimus
1
rucaparib
1
relacorilant
1
olaparib
1
nintedanib
1
nilotinib
1
liposomal doxorubicin
1
lenvatinib
1
fosaprepitant
1
atezolizumab
1
argatroban
1
Watchful Waiting
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genital Neoplasms, Female
×
fosaprepitant
×
Clear all
NCT01074697
2015-04-24
GAND-emesis
Odense University Hospital
Phase 3
Completed
246 enrolled